The health economics burden of sarcopenia: a systematic review by Bruyère, Olivier et al.
Contents lists available at ScienceDirect
Maturitas
journal homepage: www.elsevier.com/locate/maturitas
The health economics burden of sarcopenia: a systematic review
Olivier Bruyère⁎, Charlotte Beaudart, Olivier Ethgen, Jean-Yves Reginster, Médéa Locquet
World Health Organization Collaborating Center for the Public Health Aspects of Musculoskeletal Health and Aging, Department of Public Health, Epidemiology and Health
Economics, University of Liège, Liège, Belgium





A B S T R A C T
Despite of better knowledge about sarcopenia, an optimal understanding of its consequences from a public
health perspective remains a challenge. Speciﬁcally, the economic burden of the illness is unclear. As a support
for the public health policy makers and other health actors, our objective was to perform a systematic review of
the literature comparing healthcare costs between sarcopenic and non-sarcopenic patients (under the registra-
tion number CRD42018099291). A search for relevant articles was conducted on the Medline and Scopus da-
tabases. Rigorous eligibility criteria were established (e.g., subjects with sarcopenia, both men and women,
mean age of the sarcopenic population) and applied by two investigators to identify suitable studies. The ﬁrst
screening phase, performed by 2 independent reviewers, covered 455 references. Fourteen relevant studies were
included in the ﬁnal analysis. Overall, we noted an important heterogeneity between studies in the way of
assessing sarcopenia (i.e. operational deﬁnitions, tools and cut-oﬀs used). There were also large variations be-
tween studies in their cost analysis settings (i.e., discrepancies in time horizon, types and sources of economic
data). Most of the studies focused on hospitalization costs following surgery for a speciﬁc disease such as cancer.
Finally, 11 out of the 14 studies reported higher healthcare costs for sarcopenic patients. However, most of the
included studies have important methodological bias (e.g. potential confusion factors rarely taken into account),
and low to moderate quality scores. More standardized research, taking into account all the limitations of the
published studies, should be conducted to assess the true impact of sarcopenia on healthcare consumption.
1. Introduction
Sarcopenia, deﬁned as a loss of muscle mass and function, is in-
creasingly considered to be a major public health problem in the older
population and in a range of clinical settings [1,2]. Indeed, the health
consequences of sarcopenia include death, falls, new or prolonged
hospitalizations, fractures, loss of mobility and physical function, a
reduced quality of life [3–6]. Interestingly, most of these outcomes have
potential direct or indirect costs, both for the patient and the society. If
a lot of studies assessing the clinical outcomes of sarcopenia have been
published, far less studies assessing the costs of sarcopenia are avail-
able. The economic burden-of-illness due to its engendered costs is
acutely under-explored but however essential for public health policies
makers. At the population level, probably the most cited paper on the
economic burden of sarcopenia suggested that, in the United States, the
direct health care cost attributable to this disease was estimated, for the
year 2000, at $18.5 billion (i.e. 1.5% of the total healthcare ex-
penditure) [7]. It should be acknowledged that, in this particular study,
no direct individual assessment of healthcare costs was made. However,
since a couple of years, some studies have been published to assess, at
the individual level, the economic burden of sarcopenia.
The objective of the present paper is then to summarize, through a
systematic review of the literature, all available information in ob-
servational studies regarding the healthcare costs of sarcopenia com-
pared to those of individuals without the disease.
2. Methods
The research protocol has been published in July 2018 in PROSP-
ERO under the registration number CRD42018099291 (https://www.
crd.york.ac.uk/prospero/export_record_pdf.php).
For the present analysis, the Preferred Reporting Items for
Systematic Reviews and Meta-analysis (PRISMA) statement has been
rigorously followed through all steps of the research [8]. Our issue of
interest was ﬁrst correctly identiﬁed and deﬁned using the following
PICOS strategy: Population or disease – sarcopenic subjects; Interven-
tion – not applicable; Comparator – subjects without sarcopenia if
studied; Outcomes – health care costs; Study design - observational.
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The electronic databases MEDLINE (via Ovid) and Scopus were
searched on May 2018 for cross-sectional, prospective and case-control
studies, published in English or in French, reporting on an economic
analysis (i.e., monetary value) in sarcopenic individuals. No date lim-
itation was applied. The search strategy (applied on MEDLINE, via
Ovid) and search terms, both indexed and free text, used for this re-
search are detailed through Table 1. Additional relevant studies were
identiﬁed through a manual search of the bibliographic references of
relevant articles and existing reviews.
2.2. Study selection
In the initial screening stage, two investigators independently re-
viewed the title and abstract of each of the references to exclude articles
irrelevant to the systematic review, according to predeﬁned inclusion
criteria (Table 2). In the second step, the two investigators in-
dependently read the full texts of the articles that were not excluded in
the initial stage and relevant selected studies that truly met all the in-
clusion criteria. If there was any doubt or discrepancies about the in-
clusion of an article, the ﬁnal decision was undertaken through dis-
cussion and when needed, through the intervention of a third reviewer.
2.3. Data extraction
Data were extracted by one reviewer according to a standardized
data extraction form, previously pre-tested on a sample of 3 studies. All
extracted data were double checked by the second reviewer and any
diﬀerences in point of view were discussed in order to achieve con-
sensus. The following data were extracted: authors; journal name; year
of publication; country; objective of the study; socio-demographic data
(country, type of population, sex ratio, mean age); sample size; design
(number of groups, description of groups); tools and cut-oﬀs used to
assess sarcopenia (muscle mass, muscle strength and physical perfor-
mance); health economic outcome(s) in monetary value; source and
method of data collection ; perspective of cost ; time horizon of cost
data collection ; adjustment factors ; conclusion; potential conﬂicts of
interest and funding. When data of interest were missing, we system-
atically contacted authors or co-authors when information was missing
in the full-text article.
2.4. Study quality assessment
All included studies were appraised for methodological quality by
two independent reviewers using the Joanna Briggs Institute critical
appraisal tools [9]. The two reviewers critically assessed the studies
independently from each other, answering “Yes’’, “No’’, “Unclear’’, or
“Not applicable’’ to 8 questions (for cross-sectional studies), 10 ques-
tions (for case-control studies) or 11 questions (for cohort studies)
about methodological main concerns. After these two independent re-
views, the results were confronted and and any discrepancies discussed
with a third reviewer experienced in systematic reviews. Each study
was displayed with its total points, and the number of “Yes” responses
was summed for each study. We considered every study that met the
inclusion criteria, independent of their quality.
2.5. Data synthesis
A descriptive analysis of the included studies has been performed
under the format of a narrative report. Results have been structured
according to a primary description of their general characteristics,
followed by the evaluation of the intrinsic methodological quality of
studies to conclude with a description of the cost comparison analyzes
of each included references.
3. Results
3.1. Literature Search
The initial databases search yielded 450 references to systematically
assess. An additional 5 studies, identiﬁed through a manual research,
were also eligible. After the process of selection based on abstract and
title and after on the full-text article review (Fig. 1), we ﬁnally included
14 studies assessing the diﬀerence in health care costs between in-
dividuals with or without sarcopenia[10–23]. Sixteen studies were re-
jected because of duplicate (n= 2) [11, 20], wrong outcomes (n=13)
[24–36] or wrong exposure factor (n=1) [38].
Table 1
Search strategy applied on Medline (via Ovid).
1 SARCOPENIA/
2 sarcopenia.ti,ab,kf.
3 1 or 2







11 (care adj2 consumption).ti,ab,kf.
12 economic*.ti,ab,kf.
13 "cost of illness".ti,ab,kf.
14 budget*.ti,ab,kf.
15 monetary.ti,ab,kf.
16 ((resource* or drug*) adj2 (utili?ation or allocat* or use*)).ti,ab,kf.
17 ((health or healthcare or direct service* or indirect service* or hospital* or
drug*) adj2 (cost or use* or
utili?ation or resource* or consumption)).ti,ab,kf.
18 ﬁnancial.ti,ab,kf.
19 reimbursement.ti,ab,kf.
20 ((health* or care) adj2 service).ti,ab,kf.
21 (burden adj2 (illness or disease* or health*)).ti,ab,kf.
22 "informal care".ti,ab,kf.
23 ((patient or societal or health or institutional) adj2 perspective).ti,ab,kf.





29 "quality-adjusted life years".ti,ab,kf.





Design Cross-sectional studies, prospective studies and case-control studies.
Participants Subjects with sarcopenia, both men and women, mean age of a sarcopenic population, no restriction regarding ethnicity or living environment (i.e.,
community-dwelling, institutionalized, hospitalized).
Diagnosis of sarcopenia Any diagnosis criteria
Outcome Health care costs/expenditures: expenditure on health care to be expressed in terms of monetary units, regardless of the manner by which it has been
reported (e.g. based on care certiﬁcates, questionnaires, self-reports, medical records, etc.).
Language French or English
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3.2. Characteristics of the included studies
A complete presentation of the characteristics and design of the 14
included studies [10–23] is accessible in Table 3. All studies, speciﬁ-
cally regarding their analysis of sarcopenia-related costs, followed a
cross-sectional design and was comprised of 50 to 1593 participants. All
were interested in both sex, with the male gender more represented
(i.e., over 50% of the general population), whose median age varied
from 48.5 to 83 years. The type of population studied diﬀered a little
between studies : most were carried out on hospitalized individuals (10
studies out of 14, 71%), after surgery (8 studies out of 14, 57%) or not,
but two studies [17,19] related to healthy community-dwelling older
adults and one to patients living in the community, but presenting a
disease (i.e., cirrhosis) [22]. Regarding diagnosis of sarcopenia, only
half of the included studies reported using a deﬁnition of the disease
recommended by scientiﬁc societies [10,12,17–19,21,23].
The way to diagnose sarcopenia was indeed very heterogeneous, the
diagnostic thresholds being also arbitrarily placed for the majority of
the included studies. For instance, 11 studies out of 14
[11–18,20,22,23] applied diagnostic thresholds according to the results
intrinsic to their own study and population (i.e., lowest tertile or
quartile) and not based on data validated and recognized in the scien-
tiﬁc literature, as used by the three other studies [10,19,21]. However,
when applicable, the cut-oﬀs used to measure muscle strength and
physical performance were all based on more robust scientiﬁc evidence.
In terms of sarcopenia costing, we observed generally fairly robust
methods of data collection (i.e., use of the institution's ﬁnancial ac-
counting system). Only one study [19] collected data on the patient's
self-report via a face-to-face questionnaire and four studies
[12,14,17,18] did not reported at all the method of collecting cost data.
3.3. Quality assessment of the included studies
All publications included were assessed for their methodological
quality by means of the Joanna Briggs Institute tool for cross-sectional
studies. The scores varied from 3 to 8 points (i.e., number summed of
“yes”). Even if one study [21] obtained the maximum score (8 points),
the other assessed studies received a moderate-quality score (around 4
points). The details of scoring are transcribed in Table 4, but, globally,
two criteria of a good methodological quality were not met for most of
the researches:
- The standardized assessment and diagnosis of the exposure (i.e.,
presence of sarcopenia or not): not met for 11 studies out of 14
[10–13,15–18,20,22,23];
- The identiﬁcation and deal of confounding factors: not met for 10
out of 14 studies[10–12,14,16–20,22].
The other quality criteria (i.e., inclusion, study settings, outcome,
and statistics) were usually well respected by the articles included in
this analysis.
3.4. Health cost comparison between individuals with or without sarcopenia
Through Table 5, a complete picture of cost comparison analyses of
the 14 included studies is available. We ﬁrst noticed that the type of
health care cost was diverse: some researches were interested in the
total costs during the hospital stay [10,13–16,18,21–23], others at the
hospitalization cost only [12,17], and others to general health care
costs for community-dwelling individuals [19,20]. Most studies re-
ported compared costs in terms of diﬀerences in monetary value. Only
one expressed this diﬀerence in percentages [10].
For the majority of studies included, we ﬁnd that health care costs
were signiﬁcantly higher for people with sarcopenia compared to
people without the disease. However, there are only two studies
[13,21] which have taken into account some confounding factors,
clearly recognized as having a signiﬁcant impact on the consumption of
health care, quite independently from the sarcopenic status, such as
age, sex, number of comorbidities and nutritional status for example.
Next, three studies [10,16,19] out of 14 have diﬀerent conclusions:
there is no signiﬁcant diﬀerence in spending on health care between
sarcopenic and non-sarcopenic populations (p-values> 0.05). It should
also be noted that the time period during which the costs are collected
in the diﬀerent studies (i.e., time horizon) varied very strongly from one
study to another, ranging from 7 days [16] to 8 years [17].
4. Discussion
At a ﬁrst glance, from this systematic review, a trend toward an
economic burden of sarcopenia is observed. However, a critical ap-
praisal of the available data reduces the scope of the results:
1 Some deﬁnitions used to assess sarcopenia were not satisfactory and
aligned with recent guidelines or recommendations for the opera-
tional deﬁnition of sarcopenia [39,40]. Indeed, half of the included
studies only assessed muscle mass and, consequently, forgot the
importance of muscle strength or physical function in sarcopenia.
2 Diﬀerent tools are used to assess muscle mass and they do not have
the same scientiﬁc value [41,42]. If, albeit not totally optimal, the
DEXA is widely used and considered as the gold standard for the
diagnosis of sarcopenia, the BIA is less reliable and accurate [42].
More importantly, the CT scan, used in the majority of the included
studies, is still considered as a tool “under investigation” for the
diagnosis of sarcopenia [42].
3 The cut-oﬀs used, both for muscle mass and muscle strength, were
heterogeneous. For the latter, this is not a major issue [43] since all
these threshold values come from published recommendations of
respectable scientiﬁc organizations [39,40,44]. The problem is more
important for some cut-oﬀs related to muscle mass assessed by CT
scan that are not published or recommended by scientiﬁc societies.
Two options are then available. The ﬁrst is the use of threshold
based on predictive value (i.e. a value below which subjects have an
increased risk of adverse outcomes). These kind of cut-oﬀ, albeit not
fully validated, could make sense. The second is the use of threshold
based on stratiﬁcation of the studied population by quartiles, tier-
tiles of other percentiles. This is much more an issue since, it that
case, the cut-oﬀ are very diﬀerent from one study to another and
subject considered as sarcopenic in one study could not be con-
sidered as such in the others. Unfortunately, most of the cut-oﬀ
Fig. 1. Detailed literature search ﬂow diagram.
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values for CT scan are based on stratiﬁcation of the studies popu-
lation, making the observed results of limited interest. For BIA, one
selected study also used this approach making again the inter-
pretation quite complex.
4 The populations in the selected papers were also heterogeneous but
a substantial proportion included subjects experiencing major sur-
geries for major diseases such as cancer. Consequently, our sum-
mary results could hardly be extrapolated to older subject.
5 In the majority of the included papers (12 studies out of 14, 86%),
the group having sarcopenia and the group who do not were not
balanced according to demographic or clinical characteristics. For
example, age could be very diﬀerent among groups and this is,
obviously, a major confounding factors when comparing the
healthcare costs between two groups. Unfortunately, adjustment for
all these potential confounding variables were rarely performed in
the included studies.
6 The costs were, in the majority of the studies, limited to those oc-
curred at the hospital immediately after the surgery. When having in
mind the long-term potential consequences of sarcopenia on frac-
tures, fall or loss of autonomy, the time frame and the setting is
probably too limited to have a global view of the economic burden
of the disease.
7 At last, the quality of most of the included studies were low to
moderate, and in a substantial proportion of them, few information
were available regarding the collection of cost data, the confounding
variables or the statistical analysis performed. It should be ac-
knowledged that most of the papers does not have the economic
burden as primary outcome and, consequently, less information
were available when presenting these data.
This work of systematic review is, to our knowledge, the ﬁrst carried
out on this theme, but, however, presents certain limitations. First, we
searched for relevant manuscripts in two databases, as recommended,
but some relevant databases were not investigated (e.g. EMBASE) due
to logistical constraints. However, manual search of other relevant ar-
ticles were performed and we do not believe that many papers were
missing. Second, we included, as discussed before, studies having used
non-validated and potentially irrelevant cut-oﬀ for the assessment of
muscle mass. Maybe that other studies using these kinds of cut-oﬀs but
without claiming that they diagnosed sarcopenia with it have been
missed with our search strategy. Third, because of the heterogeneous
nature of the selected papers, no meta-analysis has been performed and
it was not possible to assess publication bias. Lastly, we decided to
avoid transformation of all monetary units into a single one. It can be
discussed and challenged but our idea was to avoid (by us but mostly by
others) making some kind of “global summary cost of sarcopenia” that
would have been false given all limitations of the selected papers.
5. Conclusion
In conclusion, our systematic review found a large heterogeneity
between studies regarding the selected population, the time horizon,
the type and source of economic data but, globally, shows some trends
toward a more important use of healthcare resources in the sarcopenic
population. However, the heterogeneity in the tools to measure of
sarcopenia, the use of non-validated thresholds to deﬁne sarcopenia,
and the moderate or even poor methodological quality of most of the
studies, do not allow to make deﬁnitive conclusion regarding the eco-
nomic burden of sarcopenia. There is a clear need for well conducted
studies in the ﬁeld of sarcopenia regarding economic analysis.
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Quality of studies (Joanna Briggs Institute - Cross-sectional studies).
























Sousa, 2016 Yes Yes Yes Yes Yes Yes Yes Yes 8
Huang, 2016 Yes Yes Yes Yes No No Unclear Yes 5
Gani, 2016 No Yes Ni No Yes Yes Yes Yes 5
Lo, 2017 No Yes Yes No No No Yes Yes 4
Kaplan, 2016 Yes Yes Yes No No No Yes Yes 4
Lou, 2017 Yes Yes Yes No No No Unclear Yes 4
Wang, 2016 Yes Yes Yes No No No Unclear Yes 4
Kirk, 2015 No Yes No No Unclear Yes Yes Yes 4
Sheetz, 2013 Yes Yes No No Unclear Yes Yes Yes 5
Antunes, 2017 Yes Yes No No No No Yes Yes 4
Bokshan, 2017 Yes Yes No No Yes No Yes Yes 5
Chen, 2018 Yes Yes No No No No No Yes 3
Mijnarends,
2016
Yes Yes Yes Yes Yes No No Yes 6
van Vugt, 2017 Yes Yes No No No No Yes Yes 4
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